Pluristem Therapeutics, Inc. (NASDAQ:PSTI)‘s stock had its “buy” rating reaffirmed by analysts at Seaport Global Securities in a note issued to investors on Friday. They presently have a $5.00 price target on the biotechnology company’s stock. Seaport Global Securities’ price objective points to a potential upside of 233.33% from the stock’s previous close. Seaport Global Securities also issued estimates for Pluristem Therapeutics’ Q3 2018 earnings at ($0.09) EPS.
PSTI has been the topic of several other reports. Zacks Investment Research downgraded Pluristem Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. ValuEngine raised Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd. Maxim Group set a $2.00 price target on Pluristem Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $3.50 price target on shares of Pluristem Therapeutics in a research report on Tuesday, September 19th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $4.13.
Pluristem Therapeutics (PSTI) opened at 1.49 on Friday. The stock’s 50 day moving average price is $1.34 and its 200 day moving average price is $1.31. The stock’s market capitalization is $145.23 million. Pluristem Therapeutics has a 1-year low of $1.04 and a 1-year high of $1.65.
A hedge fund recently raised its stake in Pluristem Therapeutics stock. Jane Street Group LLC boosted its holdings in Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 62.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 108,830 shares of the biotechnology company’s stock after buying an additional 41,796 shares during the period. Jane Street Group LLC owned approximately 0.11% of Pluristem Therapeutics worth $134,000 as of its most recent SEC filing. 4.47% of the stock is currently owned by hedge funds and other institutional investors.
About Pluristem Therapeutics
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.